Edgewise Therapeutics Inc

NASDAQ EWTX

Data sourced from iex and EODHD
Download Data

Edgewise Therapeutics Inc Income Statement 2020 - 2024

This table shows the Income Statement for Edgewise Therapeutics Inc going from 2020 until 2024. The income statement, also known as the profit and loss statement, is a financial statement that provides a summary of a company's revenues, expenses, and net income over a specific period (such as a quarter or a year). It shows the company's ability to generate revenue, manage expenses, and ultimately determine its profitability.
Income Statement Trend Unit 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31
Revenue
M 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Cost of Revenue
M 2 2 - - - - - - - - - - - - - - -
Gross Profit
M 0 -2 - - - - - - - - - - - - - - -
Operating Expenses
M 124 113 - - - - - - - - - - - - - - -
Selling, General, and Administrative Expenses (SG&A)
M 25 23 23 21 20 18 16 15 13 11 8 6 3 2 1 1 0
Research and Development (R&D) Expenses
M 98 91 80 70 63 54 47 42 38 32 28 22 17 15 10 7 3
Other Operating Expenses
M 1 -2 - - - - - - - - - - - - - - -
Costs and Expenses
M 121 113 - - - - - - - - - - - - - - -
Operating Income
M -123 -114 -103 -91 -83 -72 -62 -57 -51 -43 -37 -27 -21 -17 -11 -7 -3
Interest Expense
M 3 -3 6 7 7 4 1 1 1 0 0 0 0 0 0 0 0
Non-operating Income/Expense
M 18 14 13 10 7 4 44 44 43 43 0 0 0 0 0 0 0
EBT
M -106 -100 -89 -81 -76 -68 -61 -56 -51 -43 -36 -27 -21 -17 -11 -7 -3
Income Tax Provision
M 3 -4 -6 -7 -7 -4 41 42 43 43 - - - - - - -
Income after Tax
M -59 -45 -62 -53 -69 -64 -102 -86 -70 -56 - - - - - - -
Non-Controlling Interest
M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Net Income
M -21 -44 -64 -81 -76 -68 -61 -56 -51 -43 -30 -21 -14 -11 -11 -7 -3
Shares (Basic, Weighted)
M - - - - - - - - - - - - - - - - -
Shares (Diluted, Weighted)
R 69,795,518.00 63,720,141.25 60,924,885.75 58,021,221.75 54,581,802.25 51,151,499.50 50,069,295.75 49,424,304.25 49,333,228.50 37,337,048.25 30,105,347.75 22,873,647.25 15,643,569.00 20,338,136.00 20,338,136.00 20,338,136.00 20,338,136.00
EBITDA
M -122 -113 -102 -91 -82 -71 -62 -57 -51 -43 -36 -27 -21 -17 -11 -7 -3
Depreciation and Amortization
M 2 2 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0
EBIT
M -124 -115 -103 -92 -83 -72 -62 -57 -51 -43 -37 -27 -21 -17 -11 -7 -3
Income from Discontinued Operations
M - - - - - - - - - - - - - - - - -
Tax Rate (Effective)
% -5.01 7.77 9.75 10.56 8.58 5.46 -82.27 -111.15 -168.04 -337.22 - - - - - - -
Earnings Per Share (EPS), Basic
M - - - - - - - - - - - - - - - - -
Earnings Per Share (EPS), Diluted
M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Gross Profit Margin
% 76.33 - - - - - - - - - - - - - - - -
Operating Income Margin
% -1,503.64 - - - - - - - - - - - - - - - -
Net Income Margin
% - - - - - - - - - - - - - - - - -
EBITDA Ratio
% -1,479.97 - - - - - - - - - - - - - - - -
EBIT Ratio
% -1,503.64 - - - - - - - - - - - - - - - -
EBT Ratio
% -1,338.50 - - - - - - - - - - - - - - - -

StockViz Staff

September 19, 2024

Any question? Send us an email